4.5 Article

ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype

Related references

Note: Only part of the references are listed.
Review Oncology

NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy

Naoki Haratake et al.

Summary: Molecular-targeted therapy has shown remarkable improvements in survival and safety for NSCLC patients compared with conventional chemotherapy. TRK inhibitors have demonstrated good efficacy for patients with NTRK gene fusion-positive solid tumors, and new-generation TRK inhibitors are being tested for resistance mutations.

CLINICAL LUNG CANCER (2021)

Article Pharmacology & Pharmacy

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors

Yuchun Niu et al.

FRONTIERS IN PHARMACOLOGY (2020)

Article Medicine, Research & Experimental

Analysis of the Clinical Relevance of Histological Classification of Benign Epithelial Salivary Gland Tumours

Henrik Hellquist et al.

ADVANCES IN THERAPY (2019)

Article Pathology

Intraductal Papillary Mucinous Neoplasms of Minor Salivary Glands With AKT1 p.Glu17Lys Mutation

Abbas Agaimy et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)

Review Oncology

NTRK fusion-positive cancers and TRK inhibitor therapy

Emiliano Cocco et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Article Biochemistry & Molecular Biology

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

Aria Vaishnavi et al.

NATURE MEDICINE (2013)